Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the ...

Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US ...

Novo Nordisk ($NVO) and Viatris ($VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic ...

Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...

Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster ...

Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

Duckhorn (NAPA) to be acquired by Butterfly Equity in $1.95B all-cash deal, with shares jumping over 100% premarket.

The net price for Ozempic is still nearly $600, over nine times as much as it costs in Germany. And the estimated net price of Wegovy is over $800, nearly 4.5 times as much as it costs in Denmark ...

WASHINGTON — For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their health. But the out-of-pocket costs can add up fast.

WASHINGTON (NEXSTAR) — The CEO behind the popular weight loss and diabetes drug Ozempic was in the hot seat on Capitol Hill. Senators pressed the drug manufacturer company Novo Nordisk over its ...